Supplementary Table 1. Detailed authors' judgment of the risk of bias of the included randomized controlled trials

Bias	Authors' judgement	Support for judgement
Berghella et al. [23] (2010)		
Random sequence generation (selection bias)	Low risk	"We conducted planned secondary analysis of the Eunice Kennedy Shriver National Institute of Child Health and Human Development-sponsored randomized trial"
Allocation concealment (selection bias)	High risk	"Women were stratified at randomization to intent to use or not use 17P"; A matched placebo injection is not provided in the control group
Blinding of participants and personnel (performance bias)	High risk	"Women were stratified at randomization to intent to use or not use 17P"; participants are not blinded
Blinding of outcome assessment (detection bias)	Low risk	No adequate information is provided; however measurement of outcome is unlikely to be influenced
Incomplete outcome data (attrition bias)	Low risk	No major missing of data
Selective reporting (reporting bias)	Low risk	Study protocol is pre-registered and available
Other bias	Low risk	No other potential source of bias
Blackwell et al. [16] (2020)		
Random sequence generation (selection bias)	Low risk	"This was a double-blind, placebo-controlled international trial"; "randomization was performed via an interactive voice response system using a computer-generated schedule"
Allocation concealment (selection bias)	Low risk	"The 17-OHPC was supplied as a sterile solution containing the active ingredient (hydroxyprogesterone caproate, 250 mg/mL), benzyl benzoate, castor oil, and benzyl alcohol. Placebo was identical, minus the active ingredient, and was matched in color and appearance compared with 17-OHPC"
Blinding of participants and personnel (performance bias)	Low risk	"The women, their caregivers, and research personnel were not informed of the study-group assignment"
Blinding of outcome assessment (detection bias)	Low risk	"The women, their caregivers, and research personnel were not informed of the study-group assignment"
Incomplete outcome data (attrition bias)	Low risk	No major missing of data
Selective reporting (reporting bias)	Low risk	Study protocol is pre-registered and available
Other bias	Low risk	No other potential source of bias
Ibrahim et al. [13] (2010)		
Random sequence generation (selection bias)	Low risk	"Randomisation was done by the use of sealed envelopes"
Allocation concealment (selection bias)	Low risk	"Randomisation was done by the use of sealed envelopes which were opened by the nurse responsible for giving the injections to all participants whether Cidolut depot or placebo"
Blinding of participants and personnel (performance bias)	Low risk	"Randomisation was done by the use of sealed envelopes which were opened by the nurse responsible for giving the injections to all participants whether Cidolut depot or placebo"
Blinding of outcome assessment (detection bias)	Low risk	No adequate information is provided; however measurement of outcome is unlikely to be influenced
Incomplete outcome data (attrition bias)	Low risk	No major missing of data
Selective reporting (reporting bias)	Low risk	Study protocol is not available but all important outcomes of interest are reported
Other bias	Low risk	No other potential source of bias

Supplementary Table 1. Continued

Bias	Authors' judgement	Support for judgement
Jafarpour et al. [17] (2020)		
Random sequence generation (selection bias)	Low risk	"The patients were randomly assigned into two equal groups using a permuted block randomization method"
Allocation concealment (selection bias)	Low risk	Unpredictable sequence, no one can predict which group they will be allocated to
Blinding of participants and personnel (performance bias)	High risk	"The control group received routine prenatal care"; no matched placebo injection is given in the control group
Blinding of outcome assessment (detection bias)	Low risk	No adequate information is provided; however measurement of outcome is unlikely to be influenced
Incomplete outcome data (attrition bias)	Low risk	No major missing of data
Selective reporting (reporting bias)	Low risk	Study protocol is pre-registered and available
Other bias	Low risk	No other potential source of bias
Meis et al. [12] (2003)		
Random sequence generation (selection bias)	Low risk	"We conducted a double-blind, placebo-controlled trial"; "computer-generated randomization sequence"; "randomly assigned by a central data center, in a 2:1 ratio"
Allocation concealment (selection bias)	Low risk	"Returning eligible patients were then assigned to receive identically appearing active (17P) or placebo (castor oil) injections prepared by a research pharmacy"
Blinding of participants and personnel (performance bias)	Low risk	"The women, their caregivers, and research personnel were not informed of the study-group assignment"
Blinding of outcome assessment (detection bias)	Low risk	"The women, their caregivers, and research personnel were not informed of the study-group assignment"
Incomplete outcome data (attrition bias)	Low risk	No major missing of data
Selective reporting (reporting bias)	Low risk	Study protocol is pre-registered and available
Other bias	Low risk	No other potential source of bias
Saghafi et al. [11] (2011)		
Random sequence generation (selection bias)	Low risk	"The participants were randomly divided into two groups"
Allocation concealment (selection bias)	Low risk	Unpredictable sequence, no one can predict which group they will be allocated to
Blinding of participants and personnel (performance bias)	High risk	"In the control group, routine perinatal care was performed"; no matched placebo injection is given in the control group
Blinding of outcome assessment (detection bias)	Low risk	No adequate information is provided; however measurement of outcome is unlikely to be influenced
Incomplete outcome data (attrition bias)	Low risk	No major missing of data
Selective reporting (reporting bias)	Low risk	Study protocol is not available but all important outcomes of interest are reported
Other bias	Low risk	No other potential source of bias

17-OHPC, 17-alpha hydroxyprogesterone caproate.